{"id":118775,"date":"2026-06-16T12:07:14","date_gmt":"2026-06-16T06:37:14","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=118775"},"modified":"2026-06-16T12:07:16","modified_gmt":"2026-06-16T06:37:16","slug":"kaya-share-price-target-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/","title":{"rendered":"Kaya Share Price Target 2026 Analyst Forecast Bull and Bear Case"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p style=\"border-left: 4px solid #1F4E79; background: #EBF3FB; padding: 10px 16px; font-style: italic;\"><em>The Kaya share price target 2026 is Rs 310, implying approximately 20 percent upside from the current market price of Rs 257.33 (NSE: KAYA). With Q4 FY26 results released in 2026 and Dermatology and Skin Care Clinics tailwinds in focus, the Rs 310 price objective is supported by the FY27 earnings recovery thesis.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/kaya\/kaya-ltd-share-price-today\">Kaya<\/a> (NSE: KAYA) is a Dermatology and Skin Care Clinics company trading at Rs 257.33 with a market capitalisation of Rs 1,029 crore. Analysts have set the <strong>Kaya share price target<\/strong> at Rs 310 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast for Kaya including sector tailwinds, key risks, and the bull and bear scenarios.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Kaya_Share_Price_Target_2026_Key_Takeaways\" title=\"Kaya Share Price Target 2026: Key Takeaways\">Kaya Share Price Target 2026: Key Takeaways<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Kaya_Company_Overview\" title=\"Kaya Company Overview\">Kaya Company Overview<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Why_Is_the_Kaya_Share_Price_Target_Set_at_Rs_310_for_2026\" title=\"Why Is the Kaya Share Price Target Set at Rs 310 for 2026\">Why Is the Kaya Share Price Target Set at Rs 310 for 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#FY27_Earnings_Recovery_and_Revenue_Acceleration\" title=\"FY27 Earnings Recovery and Revenue Acceleration\">FY27 Earnings Recovery and Revenue Acceleration<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Structural_Sector_Tailwinds_in_Dermatology_and_Skin_Care_Clinics\" title=\"Structural Sector Tailwinds in Dermatology and Skin Care Clinics\">Structural Sector Tailwinds in Dermatology and Skin Care Clinics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\" title=\"RBI Rate Cut Cycle and Lower Cost of Capital\">RBI Rate Cut Cycle and Lower Cost of Capital<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Union_Budget_2026-27_Capex_Push_and_Policy_Support\" title=\"Union Budget 2026-27 Capex Push and Policy Support\">Union Budget 2026-27 Capex Push and Policy Support<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#FII_Flow_Normalisation_After_the_2026_Tariff_Shock\" title=\"FII Flow Normalisation After the 2026 Tariff Shock\">FII Flow Normalisation After the 2026 Tariff Shock<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Kaya_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\" title=\"Kaya Share Price Targets: Short Term, 12 Month, and Long Term\">Kaya Share Price Targets: Short Term, 12 Month, and Long Term<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Short_Term_Kaya_Share_Price_Target\" title=\"Short Term Kaya Share Price Target\">Short Term Kaya Share Price Target<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#12-Month_Kaya_Share_Price_Target_2026\" title=\"12-Month Kaya Share Price Target 2026\">12-Month Kaya Share Price Target 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Long_Term_Kaya_Share_Price_Target_FY27_to_FY28\" title=\"Long Term Kaya Share Price Target: FY27 to FY28\">Long Term Kaya Share Price Target: FY27 to FY28<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Bull_Case_and_Bear_Case_Scenarios_for_Kaya_in_2026\" title=\"Bull Case and Bear Case Scenarios for Kaya in 2026\">Bull Case and Bear Case Scenarios for Kaya in 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Bull_Case_Kaya_Share_Price_Target_Rs_375\" title=\"Bull Case Kaya Share Price Target: Rs 375\">Bull Case Kaya Share Price Target: Rs 375<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Bear_Case_Kaya_Share_Price_Target_Rs_205\" title=\"Bear Case Kaya Share Price Target: Rs 205\">Bear Case Kaya Share Price Target: Rs 205<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Key_Risks_That_Could_Derail_the_Kaya_2026_Price_Objective\" title=\"Key Risks That Could Derail the Kaya 2026 Price Objective\">Key Risks That Could Derail the Kaya 2026 Price Objective<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Global_Macro_and_US_Tariff_Headwinds\" title=\"Global Macro and US Tariff Headwinds\">Global Macro and US Tariff Headwinds<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#FY27_Earnings_Miss_and_Guidance_Risk\" title=\"FY27 Earnings Miss and Guidance Risk\">FY27 Earnings Miss and Guidance Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Competitive_Intensity_Among_Dermatology_and_Skin_Care_Clinics_Peers\" title=\"Competitive Intensity Among Dermatology and Skin Care Clinics Peers\">Competitive Intensity Among Dermatology and Skin Care Clinics Peers<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Liquidity_Risk_and_FII_Selling_Pressure\" title=\"Liquidity Risk and FII Selling Pressure\">Liquidity Risk and FII Selling Pressure<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#How_to_Invest_in_Kaya_A_Step-by-Step_Approach\" title=\"How to Invest in Kaya: A Step-by-Step Approach\">How to Invest in Kaya: A Step-by-Step Approach<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#FAQs_on_Kaya_Share_Price_Target_2026\" title=\"FAQs on Kaya Share Price Target 2026\">FAQs on Kaya Share Price Target 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#What_is_the_Kaya_share_price_target_for_2026\" title=\"What is the Kaya share price target for 2026?\">What is the Kaya share price target for 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#What_was_the_Kaya_share_price_target_for_2025\" title=\"What was the Kaya share price target for 2025?\">What was the Kaya share price target for 2025?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#Is_Kaya_a_good_investment_at_Rs_25733\" title=\"Is Kaya a good investment at Rs 257.33?\">Is Kaya a good investment at Rs 257.33?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#What_are_the_key_risks_to_the_Kaya_share_price_target_2026\" title=\"What are the key risks to the Kaya share price target 2026?\">What are the key risks to the Kaya share price target 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#What_is_the_52_week_high_and_low_of_Kaya\" title=\"What is the 52 week high and low of Kaya?\">What is the 52 week high and low of Kaya?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#What_are_the_main_growth_catalysts_for_Kaya_in_2026\" title=\"What are the main growth catalysts for Kaya in 2026?\">What are the main growth catalysts for Kaya in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#How_does_Kaya_compare_to_its_peers\" title=\"How does Kaya compare to its peers?\">How does Kaya compare to its peers?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/univest.in\/blogs-2\/kaya-share-price-target-2026\/#What_is_the_Kaya_share_price_target_for_2027\" title=\"What is the Kaya share price target for 2027?\">What is the Kaya share price target for 2027?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Kaya_Share_Price_Target_2026_Key_Takeaways\"><\/span><strong>Kaya Share Price Target 2026: Key Takeaways<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Kaya share price target 2026:<\/strong> Rs 310 (20% upside from CMP Rs 257.33)<\/li>\n<li><strong>Bull case:<\/strong> Rs 375 | <strong>Bear case:<\/strong> Rs 205<\/li>\n<li><strong>Ticker:<\/strong> KAYA | <strong>Sector:<\/strong> Dermatology and Skin Care Clinics | <strong>MCap:<\/strong> Rs 1,029 crore<\/li>\n<li><strong>52W range:<\/strong> Rs 180 to Rs 436 | <strong>PE:<\/strong> 35x<\/li>\n<li><strong>Key catalyst:<\/strong> Q4 FY26 results and FY27 earnings recovery confirmation in 2026<\/li>\n<li><strong>Key risk:<\/strong> FY27 earnings miss or sustained FII outflows from Indian equities<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Kaya_Company_Overview\"><\/span><strong>Kaya Company Overview<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Kaya (NSE: KAYA) is a Mumbai-based Marico subsidiary operating 150-plus Kaya skin clinics providing medical dermatology, laser, and aesthetic treatments across India and the Middle East, with digital skincare products extending the brand into D2C channels. At CMP Rs 257.33 against a 52 week range of Rs 180 to Rs 436, the stock is trading at a meaningful discount to its 52 week high. The trailing PE is 35x and the Rs 310 analyst target implies approximately 20 percent upside from current levels. Compared to peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical, Kaya is positioned as a potential re-rating candidate on FY27 earnings delivery.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>KAYA<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Dermatology and Skin Care Clinics<\/td>\n<\/tr>\n<tr>\n<td>CMP (2026)<\/td>\n<td>Rs 257.33<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 436<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 180<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 1,029 crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing PE<\/td>\n<td>35x<\/td>\n<\/tr>\n<tr>\n<td>12-Month Analyst Target<\/td>\n<td>Rs 310<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 375<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 205<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<div style=\"background: #E8EAFF; border-radius: 14px; padding: 28px 32px 24px 32px; margin: 24px 0; font-family: -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,sans-serif; cursor: pointer; max-width: 100%; box-sizing: border-box;\">\n<p style=\"font-size: 20px; font-weight: bold; color: #0a0a23; margin: 0 0 12px 0; line-height: 1.3;\">3 Stocks Building Serious Momentum Right Now<\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">When <strong style=\"color: #0a0a23;\">Univest analysts<\/strong> identify high-conviction stock opportunities, <em>investors pay attention.<\/em><\/p>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 14px 0; line-height: 1.6;\">Our research team has shortlisted the <strong style=\"color: #0a0a23;\">Top Stocks to Buy<\/strong> based on market momentum, sector trends &amp; growth potential for 2026.<\/p>\n<ul style=\"margin: 0 0 16px 20px; padding: 0; color: #3a3a5c; font-size: 15px; line-height: 1.8;\">\n<li>Discover stocks investors are actively accumulating<\/li>\n<li>High-conviction opportunities backed by research<\/li>\n<li>Designed for the next phase of market growth<\/li>\n<\/ul>\n<p style=\"font-size: 15px; color: #3a3a5c; margin: 0 0 20px 0;\">Unlock the latest <a style=\"color: #3b7fff; font-weight: bold; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">Top Stock Picks<\/a> now on Univest<\/p>\n<p><a style=\"display: inline-block; background: #3B7FFF; color: #fff; font-size: 15px; font-weight: 600; padding: 13px 28px; border-radius: 50px; letter-spacing: 0.2px; text-decoration: none;\" href=\"https:\/\/univest.in\/user\/payment?planType=ALL_PRO%20PLANS\" target=\"_blank\" rel=\"noopener\">See the Stocks \u2192<\/a><\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"Why_Is_the_Kaya_Share_Price_Target_Set_at_Rs_310_for_2026\"><\/span><strong>Why Is the Kaya Share Price Target Set at Rs 310 for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Recovery_and_Revenue_Acceleration\"><\/span><strong>FY27 Earnings Recovery and Revenue Acceleration<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>Kaya share price target<\/strong> of Rs 310 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for a re-rating. Until FY27 PAT delivery is confirmed, the Rs 310 price objective represents a base case with execution risk attached.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Structural_Sector_Tailwinds_in_Dermatology_and_Skin_Care_Clinics\"><\/span><strong>Structural Sector Tailwinds in Dermatology and Skin Care Clinics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Dermatology and Skin Care Clinics sector is expanding on the back of India&#8217;s domestic demand growth, PLI scheme support, and rising corporate investment. Kaya&#8217;s position among peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical creates a structural growth runway. Sustained sector outperformance is one of the key conditions for the Rs 375 bull case to materialise, making sector monitoring essential for investors tracking this stock.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"RBI_Rate_Cut_Cycle_and_Lower_Cost_of_Capital\"><\/span><strong>RBI Rate Cut Cycle and Lower Cost of Capital<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s RBI rate cut cycle in 2026 is reducing borrowing costs across sectors and stimulating end market demand. For Kaya, lower interest costs improve the EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 310 analyst consensus. This rate environment is a tailwind across the Dermatology and Skin Care Clinics space.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Union_Budget_2026-27_Capex_Push_and_Policy_Support\"><\/span><strong>Union Budget 2026-27 Capex Push and Policy Support<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Budget 2026-27&#8217;s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption incentives create a favourable policy backdrop for Kaya&#8217;s Dermatology and Skin Care Clinics operations. Policy support increases the probability of Kaya achieving its FY27 earnings targets, which in turn supports the Rs 310 price objective set by analysts for 2026.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FII_Flow_Normalisation_After_the_2026_Tariff_Shock\"><\/span><strong>FII Flow Normalisation After the 2026 Tariff Shock<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 35x PE, Kaya is positioned as a beneficiary of institutional reallocation into mid-cap and small-cap Indian stocks. Sustained FII inflow is a necessary condition for re-rating the stock toward the Rs 375 bull case scenario.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Kaya_Share_Price_Targets_Short_Term_12_Month_and_Long_Term\"><\/span><strong>Kaya Share Price Targets: Short Term, 12 Month, and Long Term<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Short_Term_Kaya_Share_Price_Target\"><\/span><strong>Short Term Kaya Share Price Target<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Near-term support for Kaya is anchored near the 52 week low of Rs 180. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating. Investors eyeing a near-term entry can use the 52 week low as a key reference while awaiting the FY27 earnings confirmation that would strengthen the case for the full price objective of Rs 310.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"12-Month_Kaya_Share_Price_Target_2026\"><\/span><strong>12-Month Kaya Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 12-month <strong>Kaya share price target 2026<\/strong> is Rs 310, implying approximately 20 percent upside from CMP Rs 257.33. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows. Investors can track live price movement on NSE under the ticker KAYA to assess progress toward this target.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Long_Term_Kaya_Share_Price_Target_FY27_to_FY28\"><\/span><strong>Long Term Kaya Share Price Target: FY27 to FY28<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>long term Kaya share price target<\/strong> for the FY27 to FY28 period is Rs 375 in the bull case. Full earnings delivery, re-rating toward higher peer multiples among peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical, and sustained institutional buying are the three conditions that need to align for the stock to reach the Rs 375 level over a 2 to 3 year horizon.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Bull_Case_and_Bear_Case_Scenarios_for_Kaya_in_2026\"><\/span><strong>Bull Case and Bear Case Scenarios for Kaya in 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Bull_Case_Kaya_Share_Price_Target_Rs_375\"><\/span><strong>Bull Case Kaya Share Price Target: Rs 375<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bull case Kaya share price target<\/strong> of Rs 375 materialises when FY27 earnings beat analyst estimates, Dermatology and Skin Care Clinics tailwinds accelerate beyond consensus, and FII flows return strongly to Indian equities. Under this scenario, Kaya re-rates toward higher peer multiples, making Rs 375 achievable within FY28. The current gap between CMP Rs 257.33 and Rs 375 represents approximately 45 percent potential upside.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Bear_Case_Kaya_Share_Price_Target_Rs_205\"><\/span><strong>Bear Case Kaya Share Price Target: Rs 205<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The <strong>bear case Kaya share price target<\/strong> of Rs 205 materialises if FY27 earnings disappoint, management guides below expectations, or sustained FII outflows depress the broader mid-cap market. Under this scenario, the stock risks testing the 52 week low support near Rs 180, and investors should reassess the investment thesis before adding more capital.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target<\/th>\n<th>Key Conditions<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 375<\/td>\n<td>FY27 earnings beat, sector re-rating, FII inflows<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Analyst Target)<\/td>\n<td>Rs 310<\/td>\n<td>In-line FY27 delivery, partial FII recovery<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 205<\/td>\n<td>FY27 miss, guidance cut, FII outflows persist<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_That_Could_Derail_the_Kaya_2026_Price_Objective\"><\/span><strong>Key Risks That Could Derail the Kaya 2026 Price Objective<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Global_Macro_and_US_Tariff_Headwinds\"><\/span><strong>Global Macro and US Tariff Headwinds<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The prolonged tariff tension triggered by the US reciprocal tariff announcement in 2026 has reduced FII risk appetite for Indian equities. A global demand slowdown or escalation in trade tensions remains the most prominent macro risk to the <strong>Kaya share price target<\/strong> of Rs 310 and could push the stock toward the bear case of Rs 205.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"FY27_Earnings_Miss_and_Guidance_Risk\"><\/span><strong>FY27 Earnings Miss and Guidance Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Any FY27 earnings miss or downward guidance revision by Kaya&#8217;s management would compress valuation multiples. This is the most direct company-specific risk to the Rs 310 analyst price objective. Investors should monitor quarterly results and management commentary closely, especially any signals about demand environment, pricing power, or margin compression in the Dermatology and Skin Care Clinics segment.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Competitive_Intensity_Among_Dermatology_and_Skin_Care_Clinics_Peers\"><\/span><strong>Competitive Intensity Among Dermatology and Skin Care Clinics Peers<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Intensifying competition from peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical could compress Kaya&#8217;s market share and pricing power over the medium term. This structural risk must be weighed when assessing how defensible the earnings trajectory that underpins the Rs 310 analyst target truly is, particularly as new entrants and imports from China disrupt established market structures.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Liquidity_Risk_and_FII_Selling_Pressure\"><\/span><strong>Liquidity Risk and FII Selling Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level operational improvement. For smaller market cap stocks, liquidity constraints can amplify drawdowns significantly. Investors should size positions carefully and maintain stop losses to protect capital if the broader market de-rating continues through FY27.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Kaya_A_Step-by-Step_Approach\"><\/span><strong>How to Invest in Kaya: A Step-by-Step Approach<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Check the Univest Screener for live data<\/strong><\/a><\/p>\n<p>Before considering any investment based on the <strong>Kaya share price target<\/strong> of Rs 310, review the company&#8217;s Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, operating margin trends, debt levels, and management commentary on Dermatology and Skin Care Clinics sector demand and competition.<\/p>\n<p>Open a Demat and trading account with a SEBI registered stockbroker to trade Kaya (NSE: KAYA) with regulatory protection. Complete KYC, and before executing any order, study the competitive landscape among peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical to assess whether Kaya&#8217;s competitive position justifies the Rs 310 valuation.<\/p>\n<p>Plan your entry using technical and fundamental triggers. The 52 week low of Rs 180 acts as a key support reference. A confirmed FY27 earnings uptick combined with positive guidance would validate the entry case. Always set a pre-defined stop loss below the 52 week low to limit downside.<\/p>\n<p>Maintain position sizing discipline. Restrict any single stock to 3 to 5 percent of your total equity portfolio. This is especially important in the Dermatology and Skin Care Clinics space where sectoral cycles, regulatory changes, and commodity price swings can amplify volatility beyond initial expectations.<\/p>\n<p>Always consult a SEBI registered financial advisor before making investment decisions based on any analyst price target or market commentary. SEBI Registration No. INH000013776.<\/p>\n<p><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track Kaya&#8217;s live share price and receive daily stock recommendations from SEBI registered analysts.<\/em><\/p>\n<div style=\"background: #C0392B; padding: 20px 24px; border-radius: 4px; margin: 24px 0;\">\n<p style=\"color: #ffffff; font-size: 15px; font-weight: bold; margin: 0; line-height: 1.7;\"><strong>Disclaimer Note:<\/strong> The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.<\/p>\n<\/div>\n<h2><span class=\"ez-toc-section\" id=\"FAQs_on_Kaya_Share_Price_Target_2026\"><\/span><strong>FAQs on Kaya Share Price Target 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Kaya_share_price_target_for_2026\"><\/span><strong>What is the Kaya share price target for 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Kaya share price target 2026 is Rs 310, implying approximately 20 percent upside from CMP Rs 257.33. The bull case estimate is Rs 375 and the bear case is Rs 205.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Kaya_share_price_target_for_2025\"><\/span><strong>What was the Kaya share price target for 2025?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 2025 price target for Kaya was based on FY26 earnings projections. The current 2026 analyst consensus stands at Rs 310, reflecting FY27 growth potential from CMP Rs 257.33.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Kaya_a_good_investment_at_Rs_25733\"><\/span><strong>Is Kaya a good investment at Rs 257.33?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> At Rs 257.33, Kaya offers potential upside toward Rs 310 if FY27 earnings recover as projected. Whether the stock is a good buy depends on individual risk appetite, investment horizon, and portfolio goals. Consult a SEBI registered financial advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_to_the_Kaya_share_price_target_2026\"><\/span><strong>What are the key risks to the Kaya share price target 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key risks to the Kaya share price target of Rs 310 include FY27 earnings miss, global tariff headwinds, sustained FII outflows, and competitive pressure in the Dermatology and Skin Care Clinics sector. Monitoring quarterly results closely is essential.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_52_week_high_and_low_of_Kaya\"><\/span><strong>What is the 52 week high and low of Kaya?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The 52 week high of Kaya is Rs 436 and the 52 week low is Rs 180. At CMP Rs 257.33, the stock is trading below its 52 week high and offers upside potential toward the Rs 310 analyst price objective.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_main_growth_catalysts_for_Kaya_in_2026\"><\/span><strong>What are the main growth catalysts for Kaya in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Primary growth catalysts for Kaya in 2026 include FY27 PAT recovery, Dermatology and Skin Care Clinics sector tailwinds, RBI rate cuts reducing cost of capital, Union Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_Kaya_compare_to_its_peers\"><\/span><strong>How does Kaya compare to its peers?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Kaya operates in Dermatology and Skin Care Clinics alongside peers in aesthetic healthcare like Strides Pharma and Indraprastha Medical. At CMP Rs 257.33 with MCap Rs 1,029 crore, the company is positioned as a potential re-rating candidate toward the Kaya share price target of Rs 310 on FY27 earnings delivery.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Kaya_share_price_target_for_2027\"><\/span><strong>What is the Kaya share price target for 2027?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The long-term Kaya share price target for FY27 to FY28 is Rs 375 in the bull case, assuming continued earnings growth, sector re-rating, and sustained FII inflows. Consult a SEBI registered financial advisor for personalised guidance.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Kaya share price target 2026 is Rs 310, ~20% upside from CMP Rs 257.33. Bull Rs 375, bear Rs 205. 2026.<\/p>\n","protected":false},"author":35,"featured_media":119293,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-118775","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1781591841:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["83"],"rank_math_title":["Kaya Share Price Target 2026: Rs 310 Analyst Forecast"],"rank_math_description":["The Kaya share price target 2026 is Rs 310, ~20% upside from CMP Rs 257.33. Bull Rs 375, bear Rs 205. 2026."],"rank_math_focus_keyword":["Kaya share price target"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["119293"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["18276"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/06\/Kaya-Share-Price-Target-2026-Analyst-Forecast-Bull-and-Bear-Case.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/35"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=118775"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118775\/revisions"}],"predecessor-version":[{"id":119294,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/118775\/revisions\/119294"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/119293"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=118775"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=118775"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=118775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}